Expert Review of Vaccines

Papers
(The TQCC of Expert Review of Vaccines is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Relationship between attitudes toward the effectiveness of vaccine, concerns about adverse reactions, and proactively taking SARS-Cov-2 vaccine for family among medical workers in Taizhou, China192
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy171
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?92
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response91
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant 86
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States76
Parental category B vaccine hesitancy and associated factors in China: an online cross-sectional survey73
Indirect protection from rotavirus vaccines: a systematic review65
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic64
Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis60
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children59
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumo59
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection58
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review57
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays55
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis52
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era50
Evaluation strategies for measuring pneumococcal conjugate vaccine impact in low-resource settings49
Microarray patches: scratching the surface of vaccine delivery48
The important lessons lurking in the history of meningococcal epidemiology44
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom43
Effectiveness of maternal vaccination with quadrivalent inactivated influenza vaccine in pregnant women and their infants in 2019-202042
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness41
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study38
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China38
Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment36
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis36
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women36
Who is more likely to hesitate to accept COVID-19 vaccine: a cross-sectional survey in China35
Vaccines against leishmaniasis: using controlled human infection models to accelerate development34
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond34
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above33
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion33
Parental COVID-19 vaccine hesitancy: a cross-sectional survey in Italy33
Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment32
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany32
COVID-19 vaccines approved in the European Union: current evidence and perspectives32
Cost-effectiveness of cell-based influenza vaccine in France31
Looking to the future: is a universal coronavirus vaccine feasible?30
Immunization in pregnancy to protect pregnant people and their newborns against COVID-1930
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative30
Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States29
Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines29
TAK-003: development of a tetravalent dengue vaccine27
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan27
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis27
COVID-19 vaccine trials and sex-disaggregated data26
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China26
The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems26
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination25
COVID-19 vaccination and mask wearing behaviors in the United States, August 2020 - June 202125
Travelers’ preferences for tick-borne encephalitis vaccination25
Self-controlled case series design in vaccine safety: a systematic review25
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infect24
COVID-19 vaccination in pregnant and lactating women: a systematic review24
In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers24
An instrument to measure psychosocial determinants of health care professionals’ vaccination behavior: Validation of the Pro-VC-Be questionnaire23
Anti-neuraminidase immunity in the combat against influenza23
Adjuvant system AS01: from mode of action to effective vaccines23
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China23
Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis22
Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges22
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months o22
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines22
Vaccines against mpox: MVA-BN and LC16m822
Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine21
Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination21
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children21
The durability of vaccine-induced protection: an overview20
Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China20
Innovation and immunization program management: traceability and quality in Latin America and the Caribbean, laying the groundwork for a regional action plan19
Suspended cell lines for inactivated virus vaccine production19
The associations of geographic location and perceived risk of infection with the intentions to get vaccinated against COVID-19 in China19
Immunization in state of siege: the importance of thermostable vaccines for Ukraine and other war-torn countries and territories19
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?18
Safety of primary immunization with a DTwP-HBV/Hib vaccine in healthy infants: a prospective, open-label, interventional, phase IV clinical study18
Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review18
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study18
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks17
Synergistic activity of antibodies in the multicomponent 4CMenB vaccine17
To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination17
Public health impact and return on investment of the pediatric immunization program in Poland17
Estimating the time required to reach HPV vaccination targets across Europe17
Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine17
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome17
Impact of rotavirus vaccination on diarrheal disease burden of children in South America17
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States17
Development of a recombinant vaccine against human onchocerciasis17
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review17
Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?16
Next generation live-attenuated influenza vaccine platforms16
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses16
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs16
Making COVID-19 mRNA vaccines accessible: challenges resolved16
Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study16
Expert review on global real-world vaccine effectiveness against SARS-CoV-216
Eyedrop vaccination: an immunization route with promises for effective responses to pandemics16
Have mRNA vaccines sentenced DNA vaccines to death?16
A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK16
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study16
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis15
COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey15
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older15
Health behaviors are largely not predictive of adverse events following influenza vaccination15
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines14
PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients14
Correspondence on ‘Herpes Zoster and Simplex reactivation following COVID-19 vaccination’14
COVID-19 and vaccination: myths vs science14
Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza14
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice14
Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations14
Determinants of parental hesitancy to vaccinate their children against COVID-19 in China14
Vaccines against SARS-CoV-2 variants and future pandemics14
Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage13
Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions13
Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons 13
Emergence of mRNA vaccines in the management of cancer13
Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella13
Correlates of protection for meningococcal surface protein vaccines: lessons from the past13
Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data13
Lymphatic filariasis vaccine development: neglected for how long?13
Gap between willingness and behavior in the vaccination against influenza, pneumonia, and herpes zoster among Chinese aged 50–69 years13
Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution13
Vaccine for a neglected tropical disease Taenia solium cysticercosis: fight for eradication against all odds13
Rotavirus vaccines performance: dynamic interdependence of host, pathogen and environment13
0.21641302108765